Oral GABA supplements are often promoted as an effective treatment for anxiety disorders and/or as a 'natural' alternative to benzodiazepines. Unfortunately, they are snake oil.
No functioning brain is deficient in the amino acid GABA (γ-aminobutyric acid) which is the main (usually) inhibitory neurotransmitter of the brain. It is a by-product of the Krebs/citric acid cycle which converts glucose to Adenosine triphosphate (ATP) the main energy source of brain cells (and other cells of the body). As a result the brain is so awash with GABA (up to a 1,000 times more than of neurotransmitters like serotonin [1]) the blood-brain-barrier contains billions, perhaps trillions, of tiny molecular pumps to remove the excess into the blood stream for disposal [2].
What the anxious brain lacks is benzodiazepine binding sites on GABA receptors which increase the effectiveness of these receptors [3]. This is also the case for some types of epilepsy [4]. Trying to overcome this deficiency by adding more GABA is akin to trying to fix faulty spark plugs by overfilling the petrol/gas tank. Benzodiazepines work by ensuring the benzodiazepine binding sites which do exist function at maximum efficiency, not by increasing brain GABA levels as is often claimed.
References:
[1]
Olsen RW, DeLorey TM
GABA Synthesis, Uptake and Release in
Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th edition
George J Siegel ed., Lippincott Williams & Wilkins, 1999
ISBN-13: 978-0397518203
[2]
Kakee A, Takanaga H, Terasaki T, et al (2001)
Efflux of a suppressive neurotransmitter, GABA, across the blood-brain barrier.
J Neurochem. Oct;79(1):110-8 [Abstract | Full text PDF]
Terasaki T1, Hosoya K. (1999)
The blood-brain barrier efflux transporters as a detoxifying system for the brain.
Adv Drug Deliv Rev. 1999 Apr 5;36(2-3):195-209 [Abstract]
[3]
Hasler G, Nugent AC, Carlson PJ, et al. (2008)
Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography.
Arch Gen Psychiatry. Oct;65(10):1166-75 (Abstract)
Geuze E, van Berckel BN, Lammertsma AA, et al. (2007)
Reduced GABAA benzodiazepine receptor binding in veterans with post-traumatic stress disorder.
Mol Psychiatry. 2008 Jan;13(1):74-83 (Abstract)
Cameron OG, Huang GC, Nichols T, et al. (2007)
Reduced gamma-aminobutyric acid(A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder.
Arch Gen Psychiatry. Jul;64(7):793-800. (Abstract)
Bremner JD, Innis RB, Southwick SM, et al. (2000)
"Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder."
Am J Psychiatry Jul; vol 157(7):1120-6 (Abstract)
Bremner JD, Innis RB, White T, et al (2000)
"SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder."
Biol Psychiatry Jan 15; vol 47(2):96-106 (Abstract)
Malizia AL. (1999)
"What do brain imaging studies tell us about anxiety disorders? "
J Psychopharmacol Dec; vol 13(4):372-8 (Abstract)
Morimoto K. 1999
Benzodiazepine receptor imaging in the brain: recent developments and clinical validity
Kaku Igaku. May;36(4):307-13. (Abstract)
Malizia AL, Cunningham VJ, Bell CJ, et al. (1998)
"Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study." Arch Gen Psychiatry Aug; vol 55(8):715-20 (Abstract)
Tokunaga M, Ida I, Higuchi T, Mikuni M. (1997)
"Alterations of benzodiazepine receptor binding potential in anxiety and somatoform disorders measured by 123I-iomazenil SPECT." Radiat Med May-Jun; vol 15(3):163-9 (Abstract)
Uchiyama M, Sue H, Fukumitsu N, et al. (1997)
"Assessment of cerebral benzodiazepine receptor distribution in anxiety disorders by 123I-iomazenil-SPECT: comparison to cerebral perfusion scintigraphy by 123I-IMP."
Nippon Igaku Hoshasen Gakkai Zasshi Jan; vol 57(1):41-6 (Abstract)
[4]
Vivash L, Tostevin A, Liu DS, et al. (2011)
"Changes in hippocampal GABAA/cBZR density during limbic epileptogenesis: relationship to cell loss and mossy fibre sprouting."
Neurobiol Dis. Feb;41(2):227-36. (Abstract)
Morimoto K. (1999)
"Benzodiazepine receptor imaging in the brain: recent developments and clinical validity."
Kaku Igaku May; vol 36(4):307-13 (Abstract)
Savic I, Pauli S, Thorell JO, Blomqvist G. (1994)
[i]"In vivo demonstration of altered benzodiazepine receptor density in patients with generalised epilepsy."
J Neurol Neurosurg Psychiatry. Jul;57(7):797-804. [Abstract]